Valeant Pharmaceuticals International announced that it has acquired DermaTech Pty Ltd, an Australian specialty pharmaceutical company focused on dermatology products marketed throughout Australia and overseas, for approximately AU$19 million, with customary adjustments for net asset value.
This transaction significantly expands Valeants Australian specialty pharmaceutical business through the acquisition of key products in both the retail and prescription brands, which complement Valeants current product portfolio. DermaTechs current annualized net sales are approximately AU$10.5 million.
Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology.
DermaTech Pty Ltd is an Australian company specializing in the development, production and distribution of innovative products to address common dermatological conditions such as dry, itchy or sensitive skin, acne, eczema, psoriasis, contact dermatitis, insect bites, skin warts and sunburn.